Piper Sandler resumed coverage on Schrodinger with a new price target
$SDGR
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/2/2024 | $29.00 | Outperform | Leerink Partners |
| 12/5/2023 | $38.00 | Overweight | KeyBanc Capital Markets |
| 5/5/2023 | $60.00 | Overweight | Piper Sandler |
| 12/19/2022 | $23.00 | Neutral | Goldman |
| 3/1/2022 | $55.00 | Buy | Citigroup |
| 11/19/2021 | $82.00 → $49.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/19/2021 | $87.00 | Overweight | Piper Sandler |
| 11/11/2021 | $80.00 → $52.00 | Buy → Neutral | B of A Securities |
4 - Schrodinger, Inc. (0001490978) (Issuer)
3 - Schrodinger, Inc. (0001490978) (Issuer)
4 - Schrodinger, Inc. (0001490978) (Issuer)
Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch
Achieved 2024 Software Revenue of $180.4 Million, a 13.3% Increase Over 2023 Expects Software Revenue Growth of 10% to 15% and Drug Discovery Revenue of $45-50 Million in 2025 Announces Expanded Research Collaboration with Eli Lilly and Company On Track to Report Initial Phase 1 Data from Three Proprietary Programs in 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2024, and provided its financial outlook for 2025. "We are delighted with Schrödinger's excellent financial performance in 2024. Software revenue growth exceeded our expectations, showing the resilience of our business through changing indust
Schrödinger (NASDAQ:SDGR) today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E.T. Leerink Partners Global Biopharma Conference 2025: Fireside chat on Monday, March 10, 2025 at 3:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 18, 2025 at 9:00 a.m. E.T. The live discussions can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discov
Leerink Partners initiated coverage of Schrodinger with a rating of Outperform and set a new price target of $29.00
KeyBanc Capital Markets initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $38.00
Piper Sandler resumed coverage of Schrodinger with a rating of Overweight and set a new price target of $60.00
8-K - Schrodinger, Inc. (0001490978) (Filer)
10-K - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
SC 13G - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
Achieved 2024 Software Revenue of $180.4 Million, a 13.3% Increase Over 2023 Expects Software Revenue Growth of 10% to 15% and Drug Discovery Revenue of $45-50 Million in 2025 Announces Expanded Research Collaboration with Eli Lilly and Company On Track to Report Initial Phase 1 Data from Three Proprietary Programs in 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2024, and provided its financial outlook for 2025. "We are delighted with Schrödinger's excellent financial performance in 2024. Software revenue growth exceeded our expectations, showing the resilience of our business through changing indust
Schrödinger (NASDAQ:SDGR) will report its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by bi
Announces Expanded Research Collaboration Agreement with Otsuka Pharmaceutical Co., Ltd. On Track to Report Initial Phase 1 Data from Three Proprietary Programs in 2025 Focus on Delivering Continued Software Growth and Increased Drug Discovery Revenue Schrödinger, Inc. (NASDAQ:SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. "We are very proud of our accomplishments in 2024. We advanced the capabilities of our computational platform and leveraged the synergies in our business, which included signing a multi-target research collaboration and expanded software licensing agreement with Novartis. We are pleased a
Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim
Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Arun Oberoi to its Board of Directors, effective May 17, 2022. Mr. Oberoi will serve as a member of the Audit Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005040/en/Arun Oberoi was appointed to Schrödinger's Board of Directors in May 2022. He will serve on the company's Audit Committee. (Photo: Business Wire) "We are very pleased to welcome Arun to our Board," said Ramy Farid, Ph.D., president and chief executive officer of Schrödinger. "Aru